GLP-1 Market
LLY $1257.32 ▲ +0.5% NVO $38.81 ▼ -1.0% PFE $29.57 ▲ +0.4% VKTX $25.17 ▼ -8.0% KLRA $11.25 ▼ -3.9% GPCR $21.08 ▼ -5.0% RHHBY $57.11 ▲ +0.6%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Phentermine / Topiramate [Qsymia]

Company
Seattle Children's Hospital
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 17, 2026

Find a Clinical Trial Near Me

See recruiting studies for Phentermine / Topiramate [Qsymia] and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07213466

    Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder

    Not yet reported Mayo Clinic 100 participants Est. completion 2029-02-01 1 site
    Other conditions: Bipolar I Disorder, Bipolar II Disorder, Schizo Affective Disorder, Obesity, Weight Loss, GLP - 1
    View official trial listing →
  • Completed NCT NCT01922934

    A Toolbox Approach to Obesity Treatment in Primary Care

    Not yet reported Denver Health and Hospital Authority 4730 participants Est. completion 2016-08 1 site
    Other conditions: Obesity
    View official trial listing →
  • Active, not recruiting NCT NCT04881799

    Phentermine/Topiramate in Adolescents With Type 2 Diabetes and Obesity

    Not yet reported University of Minnesota 13 participants Est. completion 2026-10-27 1 site
    Other conditions: Pediatric Obesity
    View official trial listing →
  • Withdrawn NCT NCT05812183

    Gastric Sleeve-Induced Weight Loss on Shortness of Breath in Obesity

    Not yet reported University of California, Los Angeles Est. completion 2025-02-12
    Other conditions: Dyspnea, Quality of Life
    View official trial listing →
  • Active, not recruiting NCT NCT06299891

    Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity

    Not yet reported Seattle Children's Hospital 24 participants Est. completion 2026-11-30 2 sites
    Other conditions: Hypothalamic Obesity, Hypothalamic Tumor, Craniopharyngioma
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Phentermine / Topiramate [Qsymia], Phentermine / Topiramate Extended Release Oral Capsule [Qsymia]

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.